CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 608,628	$ 492,860
Marketable securities	4,550	4,941
Accounts receivable, net of allowances of $0 at December 31, 2019	295	0
Prepaid expenses	21,818	5,354
Other current assets	3,413	1,348
Total current assets	638,704	504,503
Property and equipment, net of accumulated depreciation and amortization of $7,925 and $4,316 at December 31, 2019 and 2018, respectively	32,762	23,469
Other long-term assets	256	68
Total Assets	671,722	528,040
Current Liabilities:
Accounts payable and accrued expenses	60,860	31,722
Liability related to sale of future royalties - current	3,455	0
Lease liability - current	337
Convertible senior notes, net	7,106	0
Total current liabilities	71,758	31,722
Convertible senior notes, net	0	7,055
Liability related to sale of future royalties - non-current	257,769	221,295
Deferred revenues	65,000	0
Other long-term liabilities	9,965	2,119
Total Liabilities	404,492	262,191
Commitments and Contingencies (Note 14)
Stockholders' Equity:
Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at December 31, 2019 and 2018	0	0
Common stock, $0.01 par value; authorized 250,000,000 shares; issued 212,529,313 shares and outstanding 212,409,692 shares at December 31, 2019; issued 190,445,795 shares and outstanding 190,411,070 shares at December 31, 2018	2,125	1,905
Capital contributed in excess of par	1,579,205	1,219,237
Treasury stock, at cost: 119,621 shares at December 31, 2019 and 34,725 shares at December 31, 2018	(2,095)	(824)
Accumulated deficit	(1,310,406)	(953,216)
Accumulated other comprehensive loss	(568)	(351)
Total Immunomedics, Inc. stockholders' equity	268,261	266,751
Noncontrolling interest in subsidiary	(1,031)	(902)
Total Stockholders' Equity	267,230	265,849
Total Liabilities and Stockholders' Equity	$ 671,722	$ 528,040